News | Oncology Diagnostics | March 12, 2019

Lucence Diagnostics to Develop AI Tools for Liver Cancer Treatment

Software tools would combine imaging and molecular data from liver cancer patients to help physicians make better treatment decisions

Lucence Diagnostics to Develop AI Tools for Liver Cancer Treatment

Pseudocolor accentuated CT scan image of a liver tumor. Image courtesy of Lucence Diagnostics.

March 12, 2019 — Genomic medicine company Lucence Diagnostics announced a new project to develop artificial intelligence (AI) algorithms for improving diagnosis and treatment of liver cancer. The goal is to combine the imaging and molecular data from liver cancer patients into smarter software tools that help physicians make better treatment decisions.

Lucence will be working with Olivier Gevaert, Ph.D., assistant professor of medicine (biomedical informatics) and of biomedical data science at the Stanford University School of Medicine. Having developed LiquidHallmark, which it calls the world's first liquid biopsy next-generation sequencing test that analyzes the DNA of cancer-causing mutations and viruses, Lucence will contribute its genomics expertise and proprietary sequencing technology to this project.

Liver cancer is the second leading cause of avoidable cancer deaths globally1, and hepatitis viruses contribute to the bulk of this disease. The incidence rate of liver cancer is also rising faster than any other cancer in both men and women in the United States2. The best chance of cure is surgery, and good characterization of the extent and type of the disease is critical for surgical planning. Imaging tests such as ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI) play a crucial role in the visualization of liver tumors. Fusing imaging data with sequencing data that includes both cancer mutations and viral DNA will create a unique opportunity for AI-based approaches to advance liver cancer care.

This project will evaluate a dataset of more than 5,000 patients to identify image changes and patterns that are linked to diagnostic and treatment outcomes in liver cancer.

For more information: www.lucencedx.com

References

1. Knaul F.M., Arreola-Ornelas H., Rodriguez N.M., et al. Avoidable Mortality: The Core of the Global Cancer Divide. Journal of Global Oncology, Aug. 10, 2018. DOI: 10.1200/JGO.17.00190.

2. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians, Jan. 8, 2019. DOI: 10.3322/caac.21551.

Related Content

A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Image used with permission of RSNA.

A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Read more about this case study. Image used with permission of RSNA.

Feature | Coronavirus (COVID-19) | April 09, 2021 | By Dave Fornell, Editor
While the mass COVID-19 vaccinat
Varian announced it is collaborating with Google Cloud to build an advanced artificial intelligence (AI) based diagnostic platform to aid in the fight against cancer. Varian and Google Cloud AI embarked on a deployment journey, using Neural Architecture Search (NAS) technology via Google Cloud AI Platform, to create AI models for organ segmentation — a crucial and labor-intensive step in radiation oncology that can be a bottleneck in the cancer treatment clinical workflow.
News | Artificial Intelligence | April 08, 2021
April 8, 2021 — Varian announced it is collaborating with Google...
Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

News | Artificial Intelligence | April 07, 2021
April 7, 2021 — Vysioneer, a leader in a...
Ultrasound is an invaluable diagnostic tool for the early detection of breast cancer, but the classification of lesions is sometimes challenging and time consuming. Could artificial intelligence hold the answer to solving these problems? Graphic courtesy of Chinese Medical Journal

Ultrasound is an invaluable diagnostic tool for the early detection of breast cancer, but the classification of lesions is sometimes challenging and time consuming. Could artificial intelligence hold the answer to solving these problems? Graphic courtesy of Chinese Medical Journal

News | Artificial Intelligence | April 06, 2021
April 6, 2021 — In 2020, the International Agency for Research on...
Elsevier’s STATdx, a leading radiology diagnostic decision support solution, now includes select Merit-Based Incentive Payment System (MIPS) Measures validated by MDinteractive
News | Clinical Decision Support | April 02, 2021
April 2, 2021 — Elsevier, a global leader in research publishing and information analytics, announced a partnership w
Nines announced the 510(k) FDA clearance for NinesMeasure, an innovative lung nodule measurement tool built with artificial intelligence (AI) that can accelerate diagnoses of certain respiratory diseases. 
News | Artificial Intelligence | March 30, 2021
March 30, 2021 — Nines announced the 510(k) FDA clearance for NinesMeasure, an innovative...